Severe Oral Mucositis in Pediatric Cancer Patients: Survival Analysis and Predictive Factors

Int J Environ Res Public Health. 2020 Feb 14;17(4):1235. doi: 10.3390/ijerph17041235.

Abstract

This paper investigates the occurrence of severe oral mucositis and associated factors in blood and solid cancer pediatric patients subjected to cancer treatment, using a survival analysis. A longitudinal, descriptive, observational and inductive study of 142 pediatric patients aged from 0 to 19 years was conducted from 2013 to 2017. Data were collected using a form to record the sociodemographic characteristics and health-related aspects of patients and the modified Oral Assessment Guide (OAG). Survival analysis was performed using the Kaplan-Meier method and Cox semiparametric model. The median times to occurrence of severe oral mucositis were 35.3 and 77.1 days for patients with hematologic malignancies and solid tumors, respectively. The Cox model showed that white cell changes and platelet counts as well as the use of natural chemotherapeutic agents are risk factors for the occurrence of oral mucositis among patients with hematologic malignancies. Nonetheless, among patients with solid tumors, the occurrence of oral mucositis was associated with female sex, mixed ethnicity, the presence of metastasis, abnormal creatinine levels, a combination of chemotherapy, radiotherapy, and surgery, and the administration of chemotherapeutic agents included in the miscellaneous group. The time to occurrence of severe oral mucositis and its associated factors varied according to cancer type.

Keywords: cancer; child; oral mucositis; survival analysis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antineoplastic Agents / adverse effects
  • Child
  • Child, Preschool
  • Female
  • Hematologic Neoplasms
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Neoplasms / complications*
  • Stomatitis / diagnosis
  • Stomatitis / epidemiology*
  • Survival Analysis
  • Young Adult

Substances

  • Antineoplastic Agents